MolMed Signs with GSK for Gene Therapy Development

Under the agreement, MolMed will develop a production process for an investigational gene therapy for ADA-SCID, a very rare disease that affects approximately 350 children worldwide.

Italian biotechnology company MolMed S.p.A. announced last week that it signed an agreement with GlaxoSmithKline for an investigational gene therapy.

Under the agreement,  MolMed will develop a production process for the therapy which is used to treat ADA-SCID (Adenosine Deaminase Deficiency – Severe Combined Immune Deficiency), a very rare and life-threatening disease that affects approximately 350 children worldwide. MolMed will receive up to € 5.5 million in revenues over a two-year period.

ADA-SCID is a disease caused by the alteration of a single gene; it was thus possible to develop a therapy by inserting, through gene transfer technology, the correct form of the gene into the patient’s own stem cells derived